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ABSTRACT
Neoadjuvant platin-based therapy is accepted as a standard therapy for 
advanced esophageal adenocarcinoma (EAC). Patients who respond have a better 
survival prognosis, but still a significant number of responder patients die from 
tumor recurrence. Molecular markers for prognosis in neoadjuvantly treated EAC 
patients have not been identified yet. We investigated the epidermal growth factor 
receptor (EGFR) in prognosis and chemotherapy resistance in these patients. Two 
EAC patient cohorts, either treated by neoadjuvant cisplatin-based chemotherapy 
followed by surgery (n=86) or by surgical resection (n=46) were analyzed for EGFR 
protein expression and gene copy number. Data were correlated with clinical and 
histopathological response, disease-free and overall survival.
In case of EGFR overexpression, the prognosis for neoadjuvant chemotherapy 
responders was poor as in non-responders. Responders had a significantly better 
disease-free survival than non-responders only if EGFR expression level (p=0.0152) 
or copy number (p=0.0050) was low. Comparing neoadjuvantly treated patients 
and primary resection patients, tumors of non-responder patients more frequently 
exhibited EGFR overexpression, providing evidence that EGFR is a factor for indicating 
chemotherapy resistance. 
EGFR overexpression and gene copy number are independent adverse prognostic 
factors for neoadjuvant chemotherapy-treated EAC patients, particularly for 
responders. Furthermore, EGFR overexpression is involved in resistance to cisplatin-
based neoadjuvant chemotherapy.
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INTRODUCTION 
Esophageal adenocarcinoma (EAC) is among the 
most rapidly increasing malignancies in the western 
world [1-3]. Despite improvement in surgical outcomes, 
the prognosis for EAC remains dismal with less than 
20% of patients surviving 5 years [2]. Neoadjuvant 
chemo- or radiochemotherapy followed by resection has 
been shown to provide a survival benefit for patients 
with locally advanced EAC compared to surgery alone 
[4-7]. A common therapeutic approach for these EAC 
is a multimodal treatment that includes preoperative 
application of cis-diamminedichloroplatinum II 
(cisplatin) and 5-flurouracil (5-FU) chemotherapy, 
followed by resection [4, 6-9]. Patients who respond to 
the neoadjuvant chemotherapy have a better survival 
[9-11]. Response evaluation for EAC treatment can be 
performed according to metabolic response evaluation 
using fluordeoxyglucose positron emission tomography, 
clinical response evaluation by endoscopy, endoluminal 
ultrasound and computed tomography (CT) scans, or 
histopathological response evaluation following resection. 
Until now, the histological response evaluation has been 
considered the gold standard [12, 13], and these results are 
strongly associated with survival [14-16]. It is generally 
accepted that patients with a primary tumor response have 
a significantly improved prognosis compared to patients 
who do not respond [17]; however, despite a positive 
histological response, a significant percentage of patients 
still die due to tumor recurrence [16, 18, 19]. The reasons 
for this remains unclear, and effective tools to predict 
the clinical course of patients treated with neoadjuvant 
chemotherapy are missing. The Union for International 
Cancer Control/American Joint Committee on Cancer 
(UICC/AJCC) TNM classification (7th edition) provides 
a good prognostic stratification for primary resected 
esophageal cancer, but the accuracy of this current 
classification in neoadjuvant chemotherapy-treated EAC 
remains largely unknown [13]. Therefore molecular 
markers that may determine the prognosis in neoadjuvant 
chemotherapy-treated EAC patients are urgently needed.
The epidermal growth factor receptor (EGFR) 
pathway has been recognized as one of the key proliferative 
pathways that is dysregulated during tumorigenesis, and 
this pathway is a major regulator of various signaling 
pathways involved in cell survival, migration, and tissue 
regeneration [20]. In adenocarcinomas of the esophago-
gastric junction (AEG) and the distal esophagus, EGFR 
expression has been found in approximately 30–60% 
[21, 22], while EGFR gene amplification has been 
found in 8–31% [23, 24]. Although an association of 
EGFR expression or EGFR gene amplification with poor 
prognosis in primary resection patients has been proposed 
[21, 25], the clinical and biological significance of such 
expression in neoadjuvantly treated patients remain 
undefined. To further elucidate the role of EGFR in EAC, 
we examined the EGFR protein expression and gene copy 
number changes, clinical characteristics, and outcome in 
EAC patients treated with cisplatin-based neoadjuvant 
chemotherapy. We hypothesized that EGFR in EAC 
promotes an aggressive tumor phenotype and results in 
poor outcomes and neoadjuvant chemotherapy resistance.
RESULTS
Correlation of EGFR protein expression, copy 
number changes, and clinical variables
Tissue samples of 86 patients who underwent 
neoadjuvant chemotherapy and 46 samples of patients 
treated by primary resection without chemotherapy 
were examined for EGFR protein expression and gene 
copy number changes (EGFR-to-chromosome-7 ratio) 
(Table 1). EGFR expression and copy number changes 
were significantly positively correlated in neoadjuvant 
chemotherapy-treated patients (p<0.0001) and primary 
resection patients (p=0.0057). High EGFR protein 
expression (IHC score 2+/3+) occurred in 31.4% of 
patients who received neoadjuvant chemotherapy. In 
contrast, only 13.0% of patients in the primary resection 
group demonstrated high EGFR protein expression (Table 
1). The number of patients with an EGFR gene copy 
number amplification (EGFR-to-chromosome-7 ratio 
of >2.2) in neoadjuvant chemotherapy-treated patients 
(4.7%) was comparable to that in the primary resection 
patient group (4.3%; Table 1).
EGFR overexpression is an independent adverse 
prognostic factor in EAC patients
EGFR protein expression was significantly 
associated with outcome in the whole population including 
neoadjuvant treated and primary resected patients (Figure 
1, Table 2). In the neoadjuvant treated group, EGFR 
protein expression was significantly associated with 
disease-free survival (p=0.0194; Figure 1A, Table 2). 
In primary resection patients, a significant association 
between EGFR protein expression and disease-free 
survival (p<0.0001; Figure 1G, Table 2) and overall 
survival (p<0.0001; Figure 1H, Table 2) was identified. 
Further stratification of the neoadjuvant chemotherapy 
group into responding and non-responding patients 
revealed that survival of patients who did not respond to 
chemotherapy was not associated with EGFR expression 
(Figure 1E-F, Table 2). In contrast, disease-free and 
overall survival of responding patients were significantly 
associated with the EGFR expression status (Figure 1C-D, 
Table 2). Responding patients with low EGFR expression 
profit significantly in terms of disease-free (p=0.0015; 
Figure 1C, Table 2) and overall survival (p=0.0032; Figure 
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Table 2: Correlation of EGFR protein expression and copy number changes with patient survival data
EGFR EGFR/Cep7
protein expression Ratio
EGFR-low vs EGFR-high ≤2.2 vs >2.2
P n = P n =
Disease-free survival
Neoadjuvant chemotherapy-treated EAC 
(cT3/cT4) 0.0194 71 0.7531 71
       Responder 0.0015 19 0.0359 19
       Non-responder 0.5295 43 0.6685 43
Primary resection EAC (cT3) <0.0001 46 0.8006 46
Overall survival
Neoadjuvant chemotherapy-treated EAC 
(cT3/cT4) 0.0829 73 0.3820 73
       Responder 0.0032 19 0.0359 19
       Non-responder 0.9086 43 0.4451 43
Primary resection EAC (cT3) <0.0001 46 0.7494 46
Table 3: Stepwise Cox regression analysis and hazard ratios of disease-free and overall survival with 
prognostic factors in neoadjuvant chemotherapy-treated and primary resection EAC patients
Univariate Multivariate HR 95% Confidence Intervals
Disease-free survival
Neoadjuvant chemotherapy-treated EAC
UICC staging 0.0001 0.0002 1.848 1.339 – 2.551
Responder
EGFR protein expression 0.0082 0.0050 24.004 2.612 – 220.622
ypM <0.0001 0.0036 58.135 3.785 – 892.811
Non-responder
ypM 0.0236 0.0309 2.942 1.104 – 7.839
Primary resection EAC
R 0.0459 0.0208 2.414 1.144 – 5.095
ypN 0.0300 0.0140 3.329 1.275 – 8.690
EGFR protein expression 0.0258 0.0296 1.994 1.071 – 3.716
Overall survival
Neoadjuvant chemotherapy-treated EAC
ypM <0.0001 0.0243 3.557 1.179 – 10.734
EGFR protein expression 0.0491 0.0483 1.962 1.005 – 3.829
UICC staging 0.0451 0.0488 1.512 1.002 – 2.282
Responder
ypM 0.0012 0.0017 45.854 4.206 – 499.865
EGFR protein expression 0.0037 0.0033 13.466 2.383 – 76.078
Non-responder
UICC staging 0.0095 0.0016 2.303 1.371 – 3.869
Primary resection EAC
R 0.0131 0.0047 3.111 1.415 – 6.838
ypN 0.0205 0.0137 3.578 1.298 – 9.862
EGFR protein expression 0.0405 0.0448 1.899 1.015 – 3.555
Abbreviation: HR, hazard ratio
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1D, Table 2), while high EGFR expression significantly 
shortened survival in this subgroup (Figure 1C-D, Table 
2).
Multivariate Cox regression analysis confirmed 
EGFR overexpression as an independent adverse 
prognostic factor for disease-free survival (p=0.0050; 
HR=24.004; 95% confidence intervals (CI), 2.612–
220.622) and overall survival (p=0.0033; HR=13.466; 
95% CI, 2.383–76.078) in patients who responded to 
neoadjuvant chemotherapy (Table 3). This effect was also 
observed in primary resection EAC patients with respect 
to disease-free (p=0.0296; HR=1.994; 95% CI, 1.071–
3.716) and overall survival (p=0.0448; HR=1.899; 95% 
CI, 1.015–3.555; Table 3).
Thus, EGFR protein expression is an independent 
adverse prognostic factor, in particular, patients who 
respond to neoadjuvant chemotherapy can be stratified 
into patients with a good survival prognosis with low 
EGFR protein expression and patients with a poor survival 
prognosis with high EGFR protein expression.
Figure 1: EGFR protein expression is associated with prognosis in patients treated with neoadjuvant chemotherapy 
or primary resection. (A) Disease-free and (B) overall survival of all neoadjuvant chemotherapy-treated patients. (C) Disease-free 
and (D) overall survival of responding patients. (E) Disease-free and (F) overall survival of non-responding patients. (G) Disease-free and 
(H) overall survival of primary resection patients. Patients can be stratified as patients with a good survival prognosis if EGFR protein 
expression is low and patients with a poor survival prognosis if EGFR protein expression is high.
Oncotarget6625www.impactjournals.com/oncotarget
We further evaluated the influence of EGFR protein 
expression in neoadjuvant chemotherapy-treated patients 
as a molecular factor for survival prognosis. A statistically 
significant association between low EGFR expression 
levels (EGFR-low) and disease-free survival (p=0.0152) 
and overall survival (p=0.0036) was noted in responders 
and non-responders (Figure 2A), although responders 
had a significantly better prognosis than non-responders. 
In cases where patients did not respond to chemotherapy 
but had low EGFR protein expression, after surviving the 
first two years after therapy, their disease-free and overall 
survival was as good as that for responder patients. In 
contrast to these findings, in patients with high EGFR 
expression, the prognosis for responders was as poor as 
that for non-responders (Figure 2C). Thus, neoadjuvant 
therapy responders with a putative good prognosis were 
identified as actually having a poor prognosis after 
neoadjuvant therapy according to EGFR overexpression.
We also evaluated these findings with regard to 
copy number changes (EGFR-to-chromosome-7 ratio) 
and obtained similar results. A statistically significant 
difference was observed in responders and non-responders 
Figure 2: EGFR overexpression and EGFR/Chromosome-7 ratio are molecular factors for stratification of patients 
after neoadjuvant chemotherapy. (A, B, C, D) Disease-free survival of neoadjuvant chemotherapy-treated patients. (A) Low EGFR 
protein expression. (B) Low EGFR/Chromosome-7 ratio. (C) High EGFR protein expression. (D) High EGFR/Chromosome-7 ratio. (E, F, 
G, H) Overall survival of neoadjuvant chemotherapy-treated patients. (E) Low EGFR protein expression. (F) Low EGFR/Chromosome-7 
ratio. (G) High EGFR protein expression. (H) High EGFR/Chromosome-7 ratio. Prognosis for neoadjuvant chemotherapy responders 
was as poor as that for non-responders when EGFR expression level was high. Responders had a significantly better prognosis than non-
responders when EGFR expression level or EGFR/Chromosome-7 ratio were low.
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between disease-free survival (p=0.0050) and overall 
survival (p=0.0032) and patients who did not have an 
EGFR amplification (Figure 2B), and a significantly 
better prognosis was predicted for responders than for 
non-responders. Identification of responder patients with 
a poor prognosis as for EGFR-high patients was not 
possible using FISH analysis in patients with an EGFR-
to-chromosome-7 ratio >2.2 due to limitations in patient 
numbers (Figure 2D).
Comparison of clinical, histopathological 
response, and EGFR expression as factors for 
prognosis
We examined EGFR protein expression with respect 
to clinical and histopathological response evaluation as a 
factor for prognosis in the neoadjuvant chemotherapy-
treated patient group. Multivariate COX regression 
analysis revealed that EGFR protein expression was 
the strongest prognostic factor for disease-free survival 
(p=0.0218; HR=2.010; 95% CI, 1.107–3.650), while 
histopathological response was the strongest factor for 
overall survival (p=0.0018; HR=3.626; 95% CI, 1.613–
8.154).
Comparison of EGFR overexpression in 
neoadjuvant chemotherapy and primary resection 
EAC patients
The frequency of EGFR overexpression in 
patients who respond to neoadjuvant chemotherapy was 
compared with the frequency of EGFR overexpression 
in EAC patients treated with primary resection without 
chemotherapy. The percentage of cases with high EGFR 
expression levels (score 2+ or 3+) was significantly more 
often found (p=0.0108) in the neoadjuvant chemotherapy-
treated cohort (31.4%, 27 of 86 vs. 13.0%, 6 of 46) 
compared to the primary resection cohort (Table 1). To 
further assess these findings, we separately compared 
the responder and the non-responder subgroup with the 
primary resection cohort. No significant difference in the 
frequency of EGFR overexpression was detected between 
chemotherapy-responders and in primary resection 
patients (p=0.2028; Figure 3A). In contrast, the frequency 
of EGFR overexpression, was significantly higher in non-
responders than in primary resection patients (p=0.0107; 
Figure 3B).
DISCUSSION
Neoadjuvant platinum-based chemotherapy is a 
standard treatment regimen for patients with advanced 
EAC [4, 7]. It is generally accepted that patients who 
respond to neoadjuvant chemotherapy have a survival 
benefit [10, 11]; however, despite a positive histological 
response, a significant number of patients die from tumor 
recurrence [16, 18, 19]. Therapeutic response of patients 
often do not prolong patient survival [26]. This might be 
due to current therapies eliminate abundant cancer cells 
but do not target stem cells [26]. In a review of concept, 
Blagosklonny pointed out further explanations [27]. The 
response-survival paradox could be explained as effective 
therapy selects for resistance among proliferating cancer 
cells [27]. Mechanisms of resistance might be either based 
nononcogenic (e.g. drug transporters and mutation in 
drug-targets) or oncogenic (e.g. apoptosis and cell cycle 
dysregulation) [27]. The oncogenic resistance is associated 
with highly aggressive cancer phenotype and, therefore no 
survival benefit [27]. The above mentioned theories might 
give an explanation for tumor recurrence in responding 
EAC patients. In the current study, we investigated EGFR 
in prognosis and chemotherapy resistance esophageal 
adenocarcinoma patients with a positive response to 
therapy but who died from tumor recurrence. EGFR, a 
receptor tyrosine kinases, is a major regulator of signaling 
pathways involved in cell survival, migration, and tissue 
regeneration [20]. Several studies have demonstrated that 
EGFR expression is a strong prognostic indicator that 
correlates with both higher recurrence rates and shorter 
survival in different tumor entities [21, 25, 28-30]. 
Additionally, studies on the EGFR status as a prognostic 
factor in patients treated by neoadjuvant chemotherapy 
have been reported [31-33]. These studies have yielded 
contradictory results across different cancer types [31-
33]. In a recently published study, EGFR overexpression 
was useful in predicting response in patients with 
triple-negative breast cancer treated with neoadjuvant 
chemotherapy [33]. In an earlier study of triple-negative 
breast cancer, patients with EGFR-positive had a less 
favorable prognosis and a poorer response to neoadjuvant 
chemotherapy than patients with EGFR-negative tumors 
[32]. On the other hand, in patients with locally advanced 
rectal cancer treated with preoperative chemoradiotherapy, 
EGFR gene copy number was neither predictive nor 
prognostic [31]. A few studies have investigated EGFR 
expression in EAC patients, but these studies have focused 
on prognosis in patients with primary resection of EAC or 
AEG. Although in these studies EGFR was associated with 
poor overall survival, a consistent association between 
EGFR and an adverse outcome was not yet substantiated 
[21, 25, 29, 30, 34]. The new finding in our study is, that 
EGFR expression predicted poorer survival outcomes in 
a subgroup of EAC patients with initial histopathologic 
response to chemotherapy. To the best of our knowledge, 
this was not yet studied before in any other population. 
In addition, in our study population of primary resection 
patients, EGFR expression was a strong and independent 
prognostic factor for disease-free and overall survival. A 
recently published study investigated factors that predict 
prognosis and recurrence in patients with esophagogastric 
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adenocarcinoma and a histopathological response with 
less than 10% residual tumor [18]. Response of the 
primary tumor did not ensure recurrence-free long-term 
survival, although complete histopathological responders 
had a better prognosis compared to partial responders [18]. 
Another recently published study defined a multifactorial 
histopathological score based on ypT category, ypN, and 
degree of histological tumor regression for the prediction 
of prognosis of resected EAC after cisplatin-based 
neoadjuvant chemotherapy [35]. Our data, however, 
demonstrated that EGFR expression or copy number 
changes are strong and independent molecular prognostic 
factors for disease-free and overall survival in patients 
with EAC who responded to neoadjuvant chemotherapy 
but had an unfavorable diagnosis.
Cisplatin is a DNA-damaging anti-tumor agent 
that activates nuclear as well as cytoplasmic signaling 
pathways involved in regulation of the cell cycle, 
damage repair, and programmed cell death [36]. EGFR 
expression may be involved in resistance to cisplatin [37, 
38]. The signals generated by DNA damage caused by 
cisplatin treatment modulate EGFR activity in EGFR-
expressing cells and suppress cell death by upregulating 
antiapoptotic proteins [37]. In addition, inhibition 
of EGFR activation enhances cisplatin-induced cell 
death [37]. Overexpression of EGFR and inhibition 
of proliferation has been observed in cisplatin-treated 
ovarian carcinoma cells, and these molecular changes 
were hypothesized to be an escape mechanism of tumor 
cells [39]. Another study demonstrated that treatment 
of chemosensitive neuroblastoma cells with cisplatin 
reversibly increased EGFR expression and that cisplatin-
resistant cells exhibited enhanced EGFR expression 
dependent of the presence of cisplatin [40]. In squamous 
cell carcinoma cells, increased EGF signaling and 
subsequent increased interleukin (IL)-1ß contributed to 
chemotherapeutic resistance [41]. Furthermore, acquired 
cisplatin resistance in EGFR-expressing lung cancer cells 
did not affect the sensitivity to EGFR tyrosine kinase 
inhibitors [42]. Together, these studies demonstrate that 
EGFR may be involved in mechanism of resistance 
to cisplatin. In the present study, we compared the 
frequency of EGFR overexpression in primary resection 
patients to neoadjuvant chemotherapy responders 
and non-responders. In the non-responding subgroup, 
EGFR expression was significantly higher than that 
in chemotherapy responders as well as in the primary 
resection patients. These findings provide evidence 
that EGFR overexpression is a factor for chemotherapy 
resistance and supports the hypothesis that EGFR is 
involved in the mechanism of resistance against cisplatin-
based neoadjuvant chemotherapy.
Resistance can be exploited for therapeutic 
advantage [43, 44]. Evolving from several decades of 
systematic research in cancer cell biology, several EGFR 
inhibitors, such as monoclonal antibodies and tyrosine 
kinase inhibitors have been developed and implemented 
in clinical application [45]. The efficacy of cetuximab in 
combination with chemotherapy was evaluated as a first-
line treatment of advanced gastric and gastro-esophageal 
junction cancer [46-49]. The overall results of these 
studies revealed response rates between 41 and 65%. 
Figure 3: Bar graphs depict EGFR expression level distribution (EGFR-high vs. EGFR-low) in comparisons of primary 
resection patients with neoadjuvant chemotherapy (A) responders and (B) non-responders. EGFR overexpression is more frequent in non-
responding patients, and thus, this overexpression can be interpreted as a factor for chemotherapy resistance.
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The efficacy of cetuximab plus capecitabin and cisplatin 
was subsequently tested in a multinational randomized 
phase III trial for the first-line treatment of patients 
with advanced gastric and gastro-esophageal junction 
cancer (EXPAND, NCT00678535) [50]. The addition of 
cetuximab to capecitabine-cisplatin provided no additional 
benefit to chemotherapy alone in the first-line treatment 
of advanced gastric or gastro-esophageal junction cancer; 
however, this study did not specifically focus on AEG 1 
patients. Therefore, studies on the effect of EGFR-directed 
therapy in AEG 1 patients have been missing but may 
be of interest in the neoadjuvant chemotherapy setting 
especially for EGFR-positive patients.
In conclusion, our data demonstrate that EGFR 
overexpression and gene copy number changes are 
independent adverse prognostic factors in EAC patients 
and may be useful molecular markers for outcome 
prediction in patients who receive neoadjuvant platin-
based chemotherapy. 
PATIENTS, MATERIALS AND METHODS
Study population
In this study, a total of 132 patients with EAC 
(all classified as type I according to Siewert [51]) were 
included. The patients were staged as cT3 or cT4 based 
on endoscopic ultrasonography and CT of the chest and 
abdomen. The study population consisted of two different 
treatment groups: one was treated with cisplatin-based 
neoadjuvant chemotherapy and the second was treated 
by primary resection without neoadjuvant chemotherapy. 
All patients provided written informed consent, and 
patient data were acquired with approval from the ethics 
committee of the Technische Universität München, 
Germany. For all patients, surgical resection material 
(formalin-fixed paraffin-embedded tissue) was available.
Neoadjuvant chemotherapy cohort
Patients (n=86) were treated with neoadjuvant 
chemotherapy consisting of two cycles of cisplatin on days 
1, 15, and 29 and folinic acid plus fluorouracil on days 1, 
8, 15, 22, 29, and 36, all repeated on day 49, as previously 
described in detail [52].
Primary resection cohort
Patients (n=46) underwent primary 
abdominothoracic esophagectomy [53] without 
chemotherapy or radiotherapy. For comparison with the 
neoadjuvant chemotherapy-treated patient group, only 
patients staged as cT3 were included in the study.
Response evaluation and follow-up
Tumor response to neoadjuvant chemotherapy was 
characterized clinically and histopathologically.
Clinical response was evaluated by endoscopy 
with endoluminal ultrasound and CT scan after the first 
and second cycle as described previously [54]. Response 
was defined as at least 50% reduction in the size of the 
primary tumor, as measured by endoscopy and imaging 
studies [55].
Histopathological tumor regression was assessed 
according to a recently published scoring system [56]. 
For the purposes of this study, all patients with fewer 
than 10% residual tumor cells (regression score 1) were 
classified as responders. All other patients were classified 
as histopathological non-responders.
Patient follow-up included endoscopy and CT of 
the chest and abdomen at 3-month intervals during the 
first year after surgery and thereafter at 6-month intervals. 
Overall survival and disease-free survival were calculated 
from the day of surgery. Survival analyses for the primary 
resection cohort were calculated from all 46 patients with 
a median follow-up of 19.9 months (range, 0.1 to 134.0 
months) for overall survival and 14.5 months (range, 
0.1 to 134.0 months) for disease-free survival. For the 
neoadjuvant chemotherapy-treated cohort, median follow-
up was 17.0 months for overall survival (range, 0.8 to 
110.4 months) and 9.2 months for disease-free survival 
(range, 0.1 to 79.8 months). The observation time was the 
interval between diagnosis and last contact (death or last 
follow-up). 
Tissue microarrays
Three representative areas of the tumor (1.0 
mm diameter) were removed from paraffin-embedded 
tissue blocks, which had been prepared at the time of 
resection, using a tissue microarray instrument (Beecher 
Instruments, Sun Prairie, Wisconsin, USA). Serial sections 
were cut for the purpose of immunohistochemistry (IHC) 
and transferred to adhesive slides using the “paraffin-tape-
transfer-system” according to manufacturer’s instructions 
(Instrumedics, Hackensack, NJ, USA).
Fluorescence in situ hybridization (FISH), 
evaluation, and image analysis
A commercially available assay with fluorescence-
labeled locus-specific DNA probes for EGFR and 
chromosome-7 centromeric α-satellite (Chrombios) was 
hybridized with the samples according to a previously 
described protocol [57]. The hybridization specificity 
of the probes was tested with metaphase spreads, and 
lymphocytes served as internal controls in tumor tissue 
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samples. Signal evaluation was performed by visual 
counting using an epifluorescence microscope equipped 
with a C-Apochromat 63x/NA 1.2 W objective and an 
AxioCam b/w charge-coupled device camera (Zeiss 
Axioplan 2, Carl Zeiss Microimaging GmbH; AxioVision 
software release 4.5) according to standard procedures. 
At least 50 tumor cells per case were selected randomly, 
whereas only cells with a minimum of one signal for 
EGFR gene and centromere-7 were chosen, and the mean 
was calculated. FISH scoring for EGFR-to-chromosome-7 
ratio was applied, and two categories were determined: 
mean ratios of ≤2.2 and >2.2. Ratios ≤2.2 were designated 
as non-amplified, while ratios >2.2 were designated as 
EGFR amplification.
Immunohistochemical analysis and reactivity 
score
EGFR immunohistochemistry was performed 
using the Dako EGFRpharmDxTM assay detection system 
(Dako Diagnostika GmbH, Hamburg, Germany) as 
described previously [58]. Tumors were considered to be 
negative when no staining or membrane staining in <10% 
neoplastic cells was observed. Weak complete and/or 
incomplete membrane staining in >10% neoplastic cells 
was considered as 1+ positive, while moderate complete 
and/or incomplete membrane staining in >10% neoplastic 
cells was considered as 2+ positive. Strong complete and/
or incomplete membrane staining in >10% neoplastic cells 
was considered as 3+ positive. Cases with a score of 0 
or 1+ were considered as EGFR-low expression cases, 
while those with a score of 2+ or 3+ were considered 
overexpression (EGFR-high) cases.
Statistical Analysis 
Correlations between variables were calculated 
using the Pearson correlation coefficient. Frequency tables 
were tested by χ2 test or Fisher exact test for comparison 
of discrete variables. Stepwise Cox regression analysis 
was applied to select parameters for predicting the overall 
survival time or disease-free survival time, their calculated 
hazard ratio are listed. Kaplan-Meier survival curves 
for different strata were plotted for overall survival and 
disease-free survival. The differences were tested by the 
log-rank test. All statistical tests were performed with SAS 
statistical package version 9.2 (SAS Institute Inc., Cary, 
NC), and significance was determined at the 95% level.
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